ChemoCentryx, Inc. Form 4 June 27, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Person

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Bekker Petrus Issuer Symbol ChemoCentryx, Inc. [CCXI] (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Director 10% Owner _X__ Officer (give title Other (specify C/O CHEMOCENTRYX, INC., 850 06/25/2013 below) **MAUDE AVENUE** SVP of Medical & Clinical (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting

MOUNTAIN VIEW, CA 94043

| (City) | (State) (Z | (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially | | | | | | | |
|--------------------------------------|---|--|---|---|------------------|-------|--|--|---|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities onAcquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | Code V | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | |
| Common Stock | 06/25/2013 | | M | 1,867 | A | \$6 | 55,461 | D | |
| Common Stock | 06/25/2013 | | S <u>(1)</u> | 1,867 | D | \$ 14 | 53,594 | D | |
| Common Stock | 06/26/2013 | | M | 117 | A | \$ 6 | 53,711 | D | |
| Common Stock | 06/26/2013 | | S <u>(1)</u> | 117 | D | \$ 14 | 53,594 | D | |
| Common Stock | 06/27/2013 | | M | 3,016 | A | \$6 | 56,610 | D | |

Edgar Filing: ChemoCentryx, Inc. - Form 4

Common Stock

06/27/2013

 $S^{(1)}$ 3,016 D

\$ 14 53,594

D

(9-02)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transacti Code (Instr. 8) | orof D Secu Acq (A) o Disp (D) | or cosed of r. 3, 4, | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | |
|---|---|---|---|---------------------------------------|---|----------------------|--|--------------------|---|---------------------------------------|
| | | | | Code V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amoun or Number of Shares |
| Employee Stock Option (right to buy) | \$ 6 | 06/25/2013 | | M | | 1,867 | 07/28/2009(2) | 07/28/2019 | Common Stock | 1,867 |
| Employee Stock Option (right to buy) | \$ 6 | 06/26/2013 | | M | | 117 | 07/28/2009(2) | 07/28/2019 | Common Stock | 117 |
| Employee Stock Option (right to buy) | \$ 6 | 06/27/2013 | | M | | 3,016 | 07/28/2009(2) | 07/28/2019 | Common Stock | 3,016 |

Reporting Owners

Relationships Reporting Owner Name / Address

> Other Director 10% Owner Officer

Bekker Petrus SVP of Medical & Clinical

C/O CHEMOCENTRYX, INC. 850 MAUDE AVENUE

2 Reporting Owners

MOUNTAIN VIEW, CA 94043

Signatures

/s/ Christopher Geissinger, as Attorney-in-Fact

06/27/2013

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- (2) As of June 25, 2013 and prior to this transaction, the option fully vested.
- (3) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3